KMT2D and melanoma: Analysis of an additional CRISPR/Cas9 genetic screen for epigenetic regulators of anti-tumor immune response in vivo revealed significant depletion of Mll4 sgRNAs in both B16 melanoma and Lewis lung carcinoma (LLC1) tumors, as well as markedly reduced representation of both Mll3 and Mll4 sgRNAs in LLC1 tumors in immunocompetent mice as compared to the corresponding tumors in immunocompromised NSG mice (Supplementary Fig. 1a), indicating an immunosuppressive function of tumor cell-intrinsic MLL3 and MLL4 in vivo as well23.